VWM
LGND icon

Vermillion Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Vermillion Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$399 – 2045
2026
Q1 		$399 Buy
+2
New +$396 ﹤0.01% 1092

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vermillion Wealth Management's LGND Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 2 shares — an estimated $399 sold.

Vermillion Wealth Management first reported a position in LGND in Q1 2026 and held it in 1 quarter. The position peaked at $399 in Q1 2026. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 2 Ligand Pharmaceuticals shares in Q2 2026, an estimated $399.
  • Vermillion Wealth Management first reported a position in Ligand Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Ligand Pharmaceuticals position peaked at $399 in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.